To evaluate health related quality of life ( HRQOL ) in TEACH , a phase III randomized placebo controlled trial of 12 months of adjuvant lapatinib in HER2 positive ( HER2 + ) early breast cancer which demonstrated marginal benefit in disease-free survival .